Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES014 in Advanced Solid Tumors
NCT05717348Phase 1Active, not recruiting
- Sponsor
- Elpiscience
- Start
- Feb 2023
- Primary completion
- Feb 2027
- Modality
- Bispecific Antibodies, Fc Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of ES014 in solid tumor (2 arms), sponsored by Elpiscience. Primary endpoints: Adverse Events and Dose Limiting Toxicity. Started Feb 2023; status: active, not recruiting.
02
Drugs
ES014
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05717348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717348.